DK1660491T3 - Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4Hmodulatorer - Google Patents

Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4Hmodulatorer

Info

Publication number
DK1660491T3
DK1660491T3 DK04779219T DK04779219T DK1660491T3 DK 1660491 T3 DK1660491 T3 DK 1660491T3 DK 04779219 T DK04779219 T DK 04779219T DK 04779219 T DK04779219 T DK 04779219T DK 1660491 T3 DK1660491 T3 DK 1660491T3
Authority
DK
Denmark
Prior art keywords
benzthiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
DK04779219T
Other languages
Danish (da)
English (en)
Inventor
Frank U Axe
Scott D Bembenek
Christopher R Butler
James P Edwards
Anne M Fourie
Cheryl A Grice
Brad M Savall
Kevin L Tays
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1660491T3 publication Critical patent/DK1660491T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Structural Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK04779219T 2003-07-28 2004-07-27 Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4Hmodulatorer DK1660491T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024050 WO2005012296A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
DK1660491T3 true DK1660491T3 (da) 2008-11-10

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04779375T DK1660492T3 (da) 2003-07-28 2004-07-27 Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4H-modulatorer
DK04779219T DK1660491T3 (da) 2003-07-28 2004-07-27 Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4Hmodulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04779375T DK1660492T3 (da) 2003-07-28 2004-07-27 Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4H-modulatorer

Country Status (28)

Country Link
US (2) US20050043378A1 (enExample)
EP (2) EP1660491B1 (enExample)
JP (2) JP2007500703A (enExample)
KR (2) KR20060054408A (enExample)
CN (2) CN1856490A (enExample)
AR (2) AR045729A1 (enExample)
AT (2) ATE403654T1 (enExample)
AU (2) AU2004261628B2 (enExample)
BR (2) BRPI0413072A (enExample)
CA (2) CA2534228A1 (enExample)
CY (1) CY1108560T1 (enExample)
DE (2) DE602004016002D1 (enExample)
DK (2) DK1660492T3 (enExample)
ES (2) ES2311858T3 (enExample)
HR (2) HRP20060041B1 (enExample)
IL (1) IL173372A (enExample)
MY (1) MY145080A (enExample)
NO (2) NO20060771L (enExample)
NZ (2) NZ544938A (enExample)
PL (2) PL1660492T3 (enExample)
PT (2) PT1660491E (enExample)
RU (2) RU2359970C2 (enExample)
SG (2) SG129449A1 (enExample)
SI (2) SI1660492T1 (enExample)
TW (2) TW200520756A (enExample)
UA (2) UA87986C2 (enExample)
WO (2) WO2005012296A1 (enExample)
ZA (2) ZA200601716B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1660492T1 (sl) * 2003-07-28 2009-02-28 Janssen Pharmaceutica Nv Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
JP2008536825A (ja) * 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
PL1877379T3 (pl) 2005-04-13 2013-06-28 Astex Therapeutics Ltd Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ES2359431T3 (es) * 2005-09-02 2011-05-23 F. Hoffmann-La Roche Ag Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina.
CA2623348A1 (en) * 2005-09-21 2007-04-12 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
US7576102B2 (en) 2005-12-21 2009-08-18 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
DK1976828T3 (en) 2005-12-29 2017-03-06 Celtaxsys Inc DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
EP2066800A2 (en) 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
BRPI0808775A2 (pt) * 2007-03-08 2017-05-30 Irm Llc compostos e composições como moduladores de atividade de gpr119
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
AR069126A1 (es) * 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
MX2010005395A (es) * 2007-11-16 2010-06-02 Abbott Lab Metodo para tratar artritis.
ES2400875T3 (es) 2008-04-11 2013-04-15 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno A4 hidrolasa
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
HRP20141038T2 (hr) 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
JP5746685B2 (ja) 2009-05-14 2015-07-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ロイコトリエンａ４加水分解酵素のモジュレーターとしての縮合二環式ヘテロアリール部分を２つ有する化合物
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
MX2015011676A (es) 2013-03-14 2016-04-25 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
DK3083562T3 (da) * 2013-12-17 2017-11-13 Lilly Co Eli Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
AU2016276316B2 (en) 2015-06-09 2020-01-23 Abbvie Inc. Nuclear receptor modulators
CN110088292A (zh) 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
AU2019278935B2 (en) 2018-05-31 2025-02-13 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
SG11202107080VA (en) * 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
CA3202720A1 (en) * 2020-11-19 2022-05-27 Telo Therapeutics, Inc. Small molecule compounds and compositions
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
HUP0100156A3 (en) * 1998-02-25 2002-12-28 Genetics Inst Inc Cambridge Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
SI1660492T1 (sl) * 2003-07-28 2009-02-28 Janssen Pharmaceutica Nv Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
ATE405562T1 (de) 2008-09-15
KR101149379B1 (ko) 2012-06-28
IL173372A (en) 2010-11-30
SG130192A1 (en) 2007-03-20
HRP20060039A2 (en) 2006-08-31
PT1660492E (pt) 2008-11-13
NO20060771L (no) 2006-04-21
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
HK1092790A1 (en) 2007-02-16
CN1860117A (zh) 2006-11-08
PL1660492T3 (pl) 2009-01-30
EP1660492A1 (en) 2006-05-31
RU2359970C2 (ru) 2009-06-27
US20050043379A1 (en) 2005-02-24
TW200520756A (en) 2005-07-01
HRP20060041B1 (hr) 2014-06-06
JP4726238B2 (ja) 2011-07-20
SI1660492T1 (sl) 2009-02-28
ES2313079T3 (es) 2009-03-01
HK1090359A1 (en) 2006-12-22
ZA200601716B (en) 2007-05-30
AU2004261628B2 (en) 2011-05-12
KR20060054408A (ko) 2006-05-22
BRPI0413072A (pt) 2006-10-03
UA82888C2 (en) 2008-05-26
SI1660491T1 (sl) 2009-02-28
ZA200601720B (en) 2007-11-28
NO20060823L (no) 2006-03-15
DE602004015620D1 (de) 2008-09-18
KR20060057593A (ko) 2006-05-26
AU2004261610B2 (en) 2010-05-20
SG129449A1 (en) 2007-02-26
CA2534228A1 (en) 2005-02-10
NZ544970A (en) 2009-02-28
AR045730A1 (es) 2005-11-09
AU2004261610A1 (en) 2005-02-10
CN100591679C (zh) 2010-02-24
PL1660491T3 (pl) 2009-01-30
RU2006102510A (ru) 2006-07-27
WO2005012297A1 (en) 2005-02-10
DE602004016002D1 (de) 2008-10-02
ES2311858T3 (es) 2009-02-16
EP1660492B1 (en) 2008-08-20
DK1660492T3 (da) 2008-11-03
RU2006102508A (ru) 2006-07-27
PT1660491E (pt) 2008-10-10
ATE403654T1 (de) 2008-08-15
TWI362383B (en) 2012-04-21
JP2007500703A (ja) 2007-01-18
UA87986C2 (uk) 2009-09-10
WO2005012296A1 (en) 2005-02-10
IL173372A0 (en) 2006-06-11
NZ544938A (en) 2009-05-31
RU2373204C2 (ru) 2009-11-20
HRP20060041A2 (en) 2006-11-30
CY1108560T1 (el) 2014-04-09
EP1660491B1 (en) 2008-08-06
BRPI0412345A (pt) 2006-10-03
AU2004261628A1 (en) 2005-02-10
CN1856490A (zh) 2006-11-01
MY145080A (en) 2011-12-15
WO2005012297A9 (en) 2007-01-04
US20050043378A1 (en) 2005-02-24
TW200523255A (en) 2005-07-16
EP1660491A1 (en) 2006-05-31
JP2007500706A (ja) 2007-01-18

Similar Documents

Publication Publication Date Title
DK1660492T3 (da) Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4H-modulatorer
DK1594867T3 (da) Phenylacetamider og deres anvendelse som glucokinasemodulatorer
IS7667A (is) Nýjar bensimídazólafleiður
DK1240164T3 (da) Benzazolderivater og deres anvendelse som JNK-modulatorer
NO20044062L (no) N-aryl-2-oksazolidinon-5-karboksamider og deres derivater og deres anvendelse som antibakterielle midler
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1956004T3 (da) Quinolinderivater og deres anvendelse som 5-HT6-ligander
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1539712T3 (da) Pyrimidinderivater og deres anvendelse som CB2-modulatorer
NO20052995D0 (no) 1,5-diaryl-pyrrol-3-karboksamid-derivater, og deres anvendelse som kannabinoid reseptormodulatorer.
NO20051236L (no) Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
NL1030324A1 (nl) Sulfonylbenzimidazoolderivaten.
NO20044665L (no) Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK1578727T3 (da) Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
NO20043794L (no) Benzensulfonamidderivater som antipsykotiske midler
NO20054674L (no) Benzotiazolderivatforbindelser, preperater og anvendelser
DK1902050T3 (da) Oxazolidinonderivater og anvendelse deraf som antibiotika
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
DK1828137T3 (da) 4-Cycloalkyl-substituerede tetrahydroquinolinderivater og deres anvendelse som medikamenter
DK1492796T3 (da) Substituerede aminoisoxazolinderivater og deres anvendelse som antidepressive midler
DK1651607T3 (da) 6-(1,1-difluoralkyl)-4-aminopicolinater og deres anvendelse som herbicider
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð